Market Research Report
COVID-19 Pandemic Mitigation Products Market 2020-2024: More Than $250 Billion/Annum, 212 Submarkets, 2 Scenarios
|Published by||Homeland Security Research Corporation (HSRC)||Product code||943034|
|Published||Content info||1020 Pages; 728 Tables & Figures
Delivery time: 1-2 business days
|COVID-19 Pandemic Mitigation Products Market 2020-2024: More Than $250 Billion/Annum, 212 Submarkets, 2 Scenarios|
|Published: June 29, 2020||Content info: 1020 Pages; 728 Tables & Figures||
No one would have believed us if last Christmas we would have said that during April & May 2020 a devastating pandemic would kill every 10 days 58,000 people, as much as the total number of Americans killed during the ten-year Vietnam war. It devastated the global economy and created an unpredicted mega market.
As early as January 20, 2020 we recruited all our analysts to research the COVID-19 pandemic mitigation related products purchases. We interviewed hundreds of experts, participated in more than 95 conferences and webinars, reviewed more than 1,500 publications and interviewed executives of more than 65 pandemic related companies.
The team which composed this report brings 43 years of hands on record in the development and commercialization of healthcare products including: antibody antigen detection, E-health, decontamination and biosecurity, PACS, teleradiology, PPE, computerized tomography, medical devices and more. Our team members bring long term relations with the U.S. FDA and CDC as well as the EU CE and other national medical regulatory agencies.
We found that this virus has created a new market worth $251-$459 Billion* per annum - the COVID-19 Pandemic Mitigation Products and Services market. To adhere to our high standards of research, as nobody can forecast the future of the pandemic, we include in the report two scenarios:
According to the ‘ COVID-19 Pandemic Mitigation Products Market - 2020-2024 ’ report scenarios, the 2020-2024 cumulative market size is expected to be $1.4-$1.9 Trillion. The U.S. and Chinese markets will dominate the global one during the forecast period.
This 1020-page 5-volume market report is the first and most comprehensive review of the global COVID-19 Pandemic Mitigation Products & Services market available today. The objective of this report is to provide today's strategic decision-makers with an expert 360-degree, time-sensitive, detailed view of this interconnected market.
The ‘COVID-19 Pandemic Mitigation Products Market - 2020-2024 ’ report presents a thorough market analysis of 54 products & services, 6 vertical, 4 revenue source, 5 regional and 13 national markets. Furthermore, the report provides updated extensive data of 37 key vendors.
As countries start to re-open, and you do your best to recover your business, the report brings to your attention multi-billion business opportunities that may assist your struggle to retain business continuity and growth. This newly formed market is not limited to the healthcare supplier's industry; many business opportunities are being created for industries from geo-surveillance to blockchain, from AI, big-data & deep learning to nonwoven fabrics.
With a highly fragmented market we address the "money trail" - each dollar spent in the global COVID-19 Pandemic Mitigation market is analyzed and crosschecked via 5 orthogonal viewpoints:
3M Company, 3Scan, Abbott , AbCellera, Advenio Technosys, Agfa Healthcare, Agilent Technologies, AiCure, Aindra, Allscripts Healthcare Solutions, Amara Health Analytics , Amazon , analyticsMD, Apixio, Apple, Arterys Inc, Atlas Wearables, Atomwise, Avalon Nutrition VITL, Babylon Health, Bay Labs, Behold.ai, benevolent.ai, BIOBEATS, BlueDot, Bollé Safety, Bullard, Buoy Health, Care Angel Wearables QorQL, Careskore, Clinithink, Cloud Pharmaceuticals, CloudMedx, CureMetrix Mental health Ginger.io, Cyrcadia, Deep 6 AI, Deep Genomics, Dell Technologies Inc., Delta Plus Group, Desktop Genetics Virtual mate Ada Health, DreaMed Diabetes, Dupont, EaglEyeMed, Eli Lilly, Encon Safety Products, Enlitic, EnsoData, Entopsis, Envisagenics Research iCarbonX, ERB Industries Inc., Ergodyne, Essilor of America, Flashback Technologies, Flow Health, Ford, Freenome, Frequency Therapeutics Inc., Fujifilm Holdings Corporation, Gateway Safety Inc., GE Healthcare, General Electric, General Motors, General Vision, Gentex Corporation, Gibco, Gilead Sciences, Globavir Biosciences, Google, Healint, Health Fidelity, HealthNextGen, HexArmor, Hindsait, Honeywell Safety Products, IBM, Imagen Technologies, Imagia Cybernetics, Infermedica, Infervision, Inovio Pharmaceuticals, Inside DNA, InSilico Medicine, Intel Corporation, Intendu, Invitrogen, Ion Torrent, Ironwear, Johnson & Johnson (Janssen), Jvion, Kapa Biosystems, Keen Eye Technologies, Kimberly-Clark Professional, Koninklijke Philips NV, Lexmark International Inc., LifeGraph, Lucina Health, Lumiata, Lunit, Lytics, Magnea, Maxim Biotech, Maxwell MRI, McKesson Corporation, MCR Safety, Medal, Medalogix, Medasense, MedAware, Medtronic, MedWhat, MedyMatch , Merck, Metabiota, Micron Technology, Microsoft Corporation, Mindshare Medical, Moderna, Morpheo, Niramai Health Analytix, Novarad Corporation, NuMedii, Numerate, Nuritas Pharma Turbine, Nvidia Corporation, Oncora Medical, Ovuline, PeerWell, Pfizer, Philips, Philips Healthcare, PhysIQ., Precision Health Intelligence, Predible Health, Profility, Proscia, pulseData, Pyramex Safety, Qualaris Healthcare Solutions, Qualcomm Incorporated, Qualcomm Incorporated, Qure. Ai, Radians Inc., Recursion Pharmaceuticals, Regeneron Pharmaceuticals, Roam Analytics , Roche, RxPREDICT, Safety Optical Service, Samsung Electronics Co., Ltd, Sanofi, Saykara, Sellstrom Manufacturing Company (SureWerx), Sense.ly, Sensory Inc., Siemens, Sigma-Aldrich Corp., Skymind Inc., Thermo Fisher Scientific, Toshiba, Vir Biotechnology Inc., VisionAid Inc., WuXi Biologics, Xilinx Inc..